Drug Type Induced pluripotent stem cells (iPSC) |
Synonyms Corneal Endothelial Cells Substitute derived from human allogeneic iPS Cells (Cellusion), CL S001 (Cellusion), CLS001 (Cellusion) |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Cellusion Inc.Startup |
Active Organization Cellusion Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bullous keratopathy | Phase 1 | JP | Cellusion Inc.Startup | 06 Jul 2023 |